Table 2.
AOP ID | Title | Molecular initiating events (MIEs) |
---|---|---|
27 | Cholestatic liver injury induced by inhibition of the bile salt export pump (ABCB11) | Bile salt export pump inhibition (ABCB11) |
34 | LXR activation leading to hepatic steatosis | LXR activation |
PPAR promoter demethylation | ||
36 | Peroxisomal Fatty Acid Beta-Oxidation inhibition leading to steatosis | PPAR-α, β, γ activation decrease |
57 | AhR activation leading to hepatic steatosis | AhR activation |
58 | CAR suppression leading to hepatic steatosis | CAR suppression |
PPAR-α inhibition | ||
LXR activation | ||
PPAR promoter demethylation | ||
59 | HNF4 α suppression leading to hepatic steatosis | HNF4 α suppression |
60 | PXR activation leading to hepatic steatosis | PXR/SXR activation |
61 | NFE2L2/FXR activation leading to hepatic steatosis | NRF2 activation |
NR1H4 activation | ||
62 | AKT2 activation leading to hepatic steatosis | Systemic inflammation leading to hepatic steatosis |
220 | CYP2E1 activation leading to liver cancer | Activation of CYP2E1 |
232 | NFE2/Nrf2 repression to steatosis | NFE2/Nrf2 repression |
273 | Mitochondrial complex inhibition leading to liver injury | Inhibition of any mitochondrial complexes (I, II, III, IV, or V) |
278 | IKK complex inhibition leading to liver injury | IKK complex inhibition |
317 | Glucocorticoid receptor activation leading to hepatic steatosis | Glucocorticoid receptor activation |